TY - JOUR
T1 - Administration of an intravenous perfluorocarbon contrast agent improves echocardiographic determination of left ventricular volumes and ejection fraction
T2 - Comparison with cine magnetic resonance imaging
AU - Hundley, W. Gregory
AU - Kizilbash, Ali M.
AU - Afridi, Imran
AU - Franco, Fatima
AU - Peshock, Ronald M
AU - Grayburn, Paul A.
N1 - Funding Information:
This study was supported in part by SONUS Pharmaceuticals, Inc., Bothell, Washington and the Society for Cardiac Angiography and Intervention.
PY - 1998/11/1
Y1 - 1998/11/1
N2 - Objectives. The purpose of this study was to determine whether contrast- enhanced transthoracic echocardiography improves the evaluation of left ventricular (LV) volumes and ejection fraction (EF). Background. Echocardiographic assessment of LV volumes and EF is widely used but may be inaccurate when the endocardium is not completely visualized. Recently the intravenous (IV) administration of perfluorocarbon microbubbles has been shown to enhance opacification of the LV cavity, but the utility of these agents to improve the echocardiographic assessment of LV systolic function is unknown. Methods. In 40 subjects (29 men and 11 women, aged 24 to 81 years) an assessment of LV volumes and EF was performed with a magnetic resonance imaging examination, followed immediately by a transthoracic echocardiogram before and after the intravenous administration of 2% dodecafluoropentane emulsion (EchoGen; Sonus Pharmaceuticals, Bothell, Washington). Results. Contrast enhanced the echocardiographic assessment of LV end diastolic volume (p<0.02), end systolic volume (p< 0.01) and LVEF (p<0.03). The percentage of subjects in whom the correct echocardiographic classification EF was normal, mild to moderately depressed or severely reduced improved significantly after contrast enhancement (from 71% before contrast to 94% after, p<0.03). These findings were most striking in the subjects with two or more adjacent endocardial segments not visualized at baseline. Conclusions. Administration of an intravenous contrast agent improves the ability to accurately assess LV volumes and EF in humans. Contrast enhancement is most useful in subjects with two or more adjacent endocardial segments not seen at baseline.
AB - Objectives. The purpose of this study was to determine whether contrast- enhanced transthoracic echocardiography improves the evaluation of left ventricular (LV) volumes and ejection fraction (EF). Background. Echocardiographic assessment of LV volumes and EF is widely used but may be inaccurate when the endocardium is not completely visualized. Recently the intravenous (IV) administration of perfluorocarbon microbubbles has been shown to enhance opacification of the LV cavity, but the utility of these agents to improve the echocardiographic assessment of LV systolic function is unknown. Methods. In 40 subjects (29 men and 11 women, aged 24 to 81 years) an assessment of LV volumes and EF was performed with a magnetic resonance imaging examination, followed immediately by a transthoracic echocardiogram before and after the intravenous administration of 2% dodecafluoropentane emulsion (EchoGen; Sonus Pharmaceuticals, Bothell, Washington). Results. Contrast enhanced the echocardiographic assessment of LV end diastolic volume (p<0.02), end systolic volume (p< 0.01) and LVEF (p<0.03). The percentage of subjects in whom the correct echocardiographic classification EF was normal, mild to moderately depressed or severely reduced improved significantly after contrast enhancement (from 71% before contrast to 94% after, p<0.03). These findings were most striking in the subjects with two or more adjacent endocardial segments not visualized at baseline. Conclusions. Administration of an intravenous contrast agent improves the ability to accurately assess LV volumes and EF in humans. Contrast enhancement is most useful in subjects with two or more adjacent endocardial segments not seen at baseline.
UR - http://www.scopus.com/inward/record.url?scp=0032213369&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032213369&partnerID=8YFLogxK
U2 - 10.1016/S0735-1097(98)00409-4
DO - 10.1016/S0735-1097(98)00409-4
M3 - Article
C2 - 9809958
AN - SCOPUS:0032213369
SN - 0735-1097
VL - 32
SP - 1426
EP - 1432
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 5
ER -